UA65525C2 - Capsules containing encapsulated cells, method for their preparation - Google Patents

Capsules containing encapsulated cells, method for their preparation Download PDF

Info

Publication number: UA65525C2
Authority: UA; Ukraine
Prior art keywords: cells; capsule; sulfate; capsule according; retroviral
Prior art date: 1995-06-27

Application number

UA97126354A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Bavarian Nordic As

Gsf Forschungszentrum Umwelt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-27

Filing date

1996-06-24

Publication date

2004-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA65525(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-06-24 Application filed by Bavarian Nordic As, Gsf Forschungszentrum Umwelt filed Critical Bavarian Nordic As

2004-04-15 Publication of UA65525C2 publication Critical patent/UA65525C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 42
239000002775 capsule Substances 0.000 title claims description 97
238000002360 preparation method Methods 0.000 title abstract description 3
108090000623 proteins and genes Proteins 0.000 claims abstract description 69
239000002245 particle Substances 0.000 claims abstract description 59
230000001177 retroviral effect Effects 0.000 claims abstract description 43
230000003612 virological effect Effects 0.000 claims abstract description 42
230000001225 therapeutic effect Effects 0.000 claims abstract description 18
238000011282 treatment Methods 0.000 claims abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
201000010099 disease Diseases 0.000 claims abstract description 3
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 46
239000013598 vector Substances 0.000 claims description 43
229920002678 cellulose Polymers 0.000 claims description 37
239000001913 cellulose Substances 0.000 claims description 37
239000003094 microcapsule Substances 0.000 claims description 26
238000004806 packaging method and process Methods 0.000 claims description 18
239000007864 aqueous solution Substances 0.000 claims description 17
206010028980 Neoplasm Diseases 0.000 claims description 15
229920000867 polyelectrolyte Polymers 0.000 claims description 15
230000001105 regulatory effect Effects 0.000 claims description 15
150000004676 glycans Chemical class 0.000 claims description 13
229920001282 polysaccharide Polymers 0.000 claims description 13
239000005017 polysaccharide Substances 0.000 claims description 13
239000003550 marker Substances 0.000 claims description 12
238000001556 precipitation Methods 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 12
239000011148 porous material Substances 0.000 claims description 11
102000004169 proteins and genes Human genes 0.000 claims description 11
239000013604 expression vector Substances 0.000 claims description 10
229920000642 polymer Polymers 0.000 claims description 10
125000001453 quaternary ammonium group Chemical group 0.000 claims description 10
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 10
229920001059 synthetic polymer Polymers 0.000 claims description 10
-1 dextran sulfate Polymers 0.000 claims description 8
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 7
239000012894 fetal calf serum Substances 0.000 claims description 7
229910052708 sodium Inorganic materials 0.000 claims description 7
239000011734 sodium Substances 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
238000001415 gene therapy Methods 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 6
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
229920002472 Starch Polymers 0.000 claims description 5
239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
229960000633 dextran sulfate Drugs 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 5
229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 5
229960002796 polystyrene sulfonate Drugs 0.000 claims description 5
239000011970 polystyrene sulfonate Substances 0.000 claims description 5
239000008107 starch Substances 0.000 claims description 5
235000019698 starch Nutrition 0.000 claims description 5
102000004127 Cytokines Human genes 0.000 claims description 3
108090000695 Cytokines Proteins 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
230000000259 anti-tumor effect Effects 0.000 claims description 2
230000000840 anti-viral effect Effects 0.000 claims description 2
230000008021 deposition Effects 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
238000005507 spraying Methods 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
239000010452 phosphate Substances 0.000 claims 2
230000002950 deficient Effects 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000003792 electrolyte Substances 0.000 claims 1
230000010076 replication Effects 0.000 claims 1
239000013603 viral vector Substances 0.000 abstract description 12
210000004027 cell Anatomy 0.000 description 184
241000700605 Viruses Species 0.000 description 23
238000002513 implantation Methods 0.000 description 17
108020004414 DNA Proteins 0.000 description 16
239000002609 medium Substances 0.000 description 15
239000013612 plasmid Substances 0.000 description 15
208000015181 infectious disease Diseases 0.000 description 14
239000012634 fragment Substances 0.000 description 12
210000005075 mammary gland Anatomy 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
230000000694 effects Effects 0.000 description 9
229940088598 enzyme Drugs 0.000 description 9
230000028993 immune response Effects 0.000 description 8
210000000056 organ Anatomy 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000001638 lipofection Methods 0.000 description 7
239000012679 serum free medium Substances 0.000 description 7
108010052832 Cytochromes Proteins 0.000 description 6
102000018832 Cytochromes Human genes 0.000 description 6
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 6
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
108010067390 Viral Proteins Proteins 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229930193140 Neomycin Natural products 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
229960004927 neomycin Drugs 0.000 description 5
238000010186 staining Methods 0.000 description 5
241001430294 unidentified retrovirus Species 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
108020004440 Thymidine kinase Proteins 0.000 description 4
108020000999 Viral RNA Proteins 0.000 description 4
102000005936 beta-Galactosidase Human genes 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000005538 encapsulation Methods 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000036541 health Effects 0.000 description 4
239000010410 layer Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
102000006382 Ribonucleases Human genes 0.000 description 3
108010083644 Ribonucleases Proteins 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010276 construction Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001493 electron microscopy Methods 0.000 description 3
238000012869 ethanol precipitation Methods 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
238000004626 scanning electron microscopy Methods 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108050004290 Cecropin Proteins 0.000 description 2
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
102000000311 Cytosine Deaminase Human genes 0.000 description 2
108010080611 Cytosine Deaminase Proteins 0.000 description 2
238000007400 DNA extraction Methods 0.000 description 2
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
229920000209 Hexadimethrine bromide Polymers 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
108010036176 Melitten Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
238000010240 RT-PCR analysis Methods 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
229960001101 ifosfamide Drugs 0.000 description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000000399 optical microscopy Methods 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000013641 positive control Substances 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003839 salts Chemical group 0.000 description 2
239000000523 sample Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000004627 transmission electron microscopy Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
230000035899 viability Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
244000005894 Albizia lebbeck Species 0.000 description 1
102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
101710167917 Carbonic anhydrase 2 Proteins 0.000 description 1
102100024633 Carbonic anhydrase 2 Human genes 0.000 description 1
241001247437 Cerbera odollam Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 1
101000799549 Homo sapiens Aspartate aminotransferase, mitochondrial Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241000514450 Podocarpus latifolius Species 0.000 description 1
ZJBMQVPEJHVSQA-OCYVVMCSSA-N Pyrromycin Chemical compound O([C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 ZJBMQVPEJHVSQA-OCYVVMCSSA-N 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
241001068263 Replication competent viruses Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000657469 Spermacoce capitata Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009432 framing Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
102000043395 human ADA Human genes 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005732 intercellular adhesion Effects 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000011435 rock Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
241000894007 species Species 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008054 sulfonate salts Chemical class 0.000 description 1
238000010998 test method Methods 0.000 description 1
QIWDGSYHBCMXSI-UHFFFAOYSA-J tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].C1=CC=CC2=C(OP([O-])([O-])=O)C(C)=CC(OP([O-])([O-])=O)=C21 QIWDGSYHBCMXSI-UHFFFAOYSA-J 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
235000020047 vermouth Nutrition 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Manufacturing Of Micro-Capsules (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

UA97126354A 1995-06-27 1996-06-24 Capsules containing encapsulated cells, method for their preparation UA65525C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK74095		1995-06-27
PCT/EP1996/002748 WO1997001357A1 (en)	1995-06-27	1996-06-24	Encapsulated cells producing viral particles

Publications (1)

Publication Number	Publication Date
UA65525C2 true UA65525C2 (en)	2004-04-15

Family

ID=8097001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA97126354A UA65525C2 (en)	1995-06-27	1996-06-24	Capsules containing encapsulated cells, method for their preparation

Country Status (21)

Country	Link
US (1)	US6776985B1 (2)
EP (1)	EP0835137B1 (2)
JP (2)	JP4119952B2 (2)
KR (1)	KR100484883B1 (2)
CN (1)	CN1187095C (2)
AT (1)	ATE309000T1 (2)
AU (1)	AU708273B2 (2)
CA (1)	CA2222559A1 (2)
CZ (1)	CZ286979B6 (2)
DE (1)	DE69633180D1 (2)
DK (1)	DK0835137T3 (2)
ES (1)	ES2253754T3 (2)
IL (1)	IL122119A (2)
NO (1)	NO321427B1 (2)
NZ (1)	NZ312671A (2)
PL (1)	PL185338B1 (2)
PT (1)	PT835137E (2)
RU (1)	RU2187301C2 (2)
SI (1)	SI0835137T1 (2)
UA (1)	UA65525C2 (2)
WO (1)	WO1997001357A1 (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE238427T1 (de)	1995-03-09	2003-05-15	Austrian Nordic Biotherapeutic	Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
WO1997001357A1 (en)	1995-06-27	1997-01-16	Bavarian Nordic Research Institute A/S	Encapsulated cells producing viral particles
US6540995B1 (en)	1996-03-27	2003-04-01	Bavarian Nordic Research Institute Gmbh	Encapsulated cells producing cytochrome P450
IL125795A0 (en)	1996-03-27	1999-04-11	Bavarian Nordic Res Inst As	Retroviral vectors encoding a cytochrome p450 gene
CN1266362A (zh)	1998-05-05	2000-09-13	皇家菲利浦电子有限公司	包括具有刷毛区和齿间刷毛区的毛刷件的牙刷
PL1745069T3 (pl)	2004-03-30	2009-10-30	Nsgene As	Zastosowanie terapeutyczne czynnika wzrostu NSG33
CA2606858A1 (en)	2005-05-03	2006-11-09	Veterinarmedizinische Universitat Wien	Permeable capsules
CN101903049B (zh)	2007-12-20	2014-08-13	伊西康公司	包囊的肾组织
KR101250925B1 (ko) *	2011-10-28	2013-04-04	한화케미칼 주식회사	캡슐 세포용 구조체
GB201408233D0 (en)	2014-05-09	2014-06-25	Austrianova Singapore Pte Ltd	Use of polyanionic composition
JP7110096B2 (ja) *	2015-11-24	2022-08-01	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	レトロウイルス産生のための一時的トランスフェクション法
EP3380604B1 (en) *	2015-11-24	2022-12-28	GlaxoSmithKline Intellectual Property Development Limited	Stable cell lines for retroviral production
AU2017269371B2 (en)	2016-05-25	2021-08-05	Lonza Houston Inc.	Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt
RU2688383C2 (ru) *	2017-07-10	2019-05-21	Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского"	Способ синтеза белка в культуре бактериальных клеток
JP2024521108A (ja) *	2021-05-21	2024-05-28	バイオナットラブスリミテッド	局所的な治療的処置のためのシステム及び方法
CN115820683B (zh) *	2022-09-28	2024-04-05	西南大学	家蚕Cyp9a20基因及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4391909A (en) *	1979-03-28	1983-07-05	Damon Corporation	Microcapsules containing viable tissue cells
DD160393A3 (de) *	1980-11-14	1983-07-27	Horst Dautzenberg	Mikrokapseln und verfahren zu ihrer herstellung
US4686098A (en) *	1984-05-14	1987-08-11	Merck & Co., Inc.	Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4680174A (en) *	1984-05-24	1987-07-14	Damon Biotech, Inc.	Induction of immune response by immunization with encapsulated antigen-producing cells
EP0199362A3 (en) *	1985-04-26	1987-10-07	Massachusetts Institute Of Technology	System and apparatus for delayed and pulsed release of biologically active substances
CA1310924C (en) *	1986-04-24	1992-12-01	Francis P. Mccormick	Infective drug delivery system
JPH02504344A (ja)	1988-05-17	1990-12-13	スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ	レトロウイルスベクター
US5328470A (en) *	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE4021050A1 (de) *	1990-06-29	1992-01-02	Akad Wissenschaften Ddr	Verfahren zur herstellung von mikrokapseln
CA2051288C (en) *	1990-09-14	2002-02-05	Robert L. Martuza	Viral targeted destruction of neoplastic cells
CA2098510A1 (en) *	1990-12-13	1992-06-14	Kenneth W. Culver	Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
WO1994029437A1 (en)	1993-06-07	1994-12-22	University Of Medicine & Dentistry Of New Jersey	Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en)	1994-08-17	1997-11-18	The General Hospital Corporation	Method of selectively destroying neoplastic cells
MX9701544A (es)	1994-09-02	1998-03-31	Gsf Forschungszentrum Umwelt	Vectores de expresion retrovirales dirigidos, no autoinactivantes.
WO1997001357A1 (en)	1995-06-27	1997-01-16	Bavarian Nordic Research Institute A/S	Encapsulated cells producing viral particles
AU6987696A (en)	1995-09-06	1997-03-27	Bavarian Nordic Research Institute A/S	The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
IL125795A0 (en)	1996-03-27	1999-04-11	Bavarian Nordic Res Inst As	Retroviral vectors encoding a cytochrome p450 gene

1996
- 1996-06-24 WO PCT/EP1996/002748 patent/WO1997001357A1/en not_active Ceased
- 1996-06-24 IL IL12211996A patent/IL122119A/en not_active IP Right Cessation
- 1996-06-24 CZ CZ19974195A patent/CZ286979B6/cs not_active IP Right Cessation
- 1996-06-24 JP JP50416597A patent/JP4119952B2/ja not_active Expired - Lifetime
- 1996-06-24 EP EP96923905A patent/EP0835137B1/en not_active Expired - Lifetime
- 1996-06-24 CA CA002222559A patent/CA2222559A1/en not_active Abandoned
- 1996-06-24 SI SI9630729T patent/SI0835137T1/sl unknown
- 1996-06-24 DE DE69633180T patent/DE69633180D1/de not_active Expired - Lifetime
- 1996-06-24 AT AT96923905T patent/ATE309000T1/de not_active IP Right Cessation
- 1996-06-24 AU AU64154/96A patent/AU708273B2/en not_active Expired
- 1996-06-24 PL PL96324289A patent/PL185338B1/pl not_active IP Right Cessation
- 1996-06-24 DK DK96923905T patent/DK0835137T3/da active
- 1996-06-24 NZ NZ312671A patent/NZ312671A/xx not_active IP Right Cessation
- 1996-06-24 PT PT96923905T patent/PT835137E/pt unknown
- 1996-06-24 CN CNB961950501A patent/CN1187095C/zh not_active Expired - Fee Related
- 1996-06-24 RU RU98101362/13A patent/RU2187301C2/ru not_active IP Right Cessation
- 1996-06-24 KR KR1019970709807A patent/KR100484883B1/ko not_active Expired - Lifetime
- 1996-06-24 UA UA97126354A patent/UA65525C2/uk unknown
- 1996-06-24 ES ES96923905T patent/ES2253754T3/es not_active Expired - Lifetime
1997
- 1997-12-10 NO NO19975813A patent/NO321427B1/no not_active IP Right Cessation
- 1997-12-23 US US08/996,460 patent/US6776985B1/en not_active Expired - Lifetime
2007
- 2007-11-21 JP JP2007301109A patent/JP4848348B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0835137A1 (en)	1998-04-15
PL185338B1 (pl)	2003-04-30
NZ312671A (en)	1999-10-28
IL122119A (en)	2004-06-01
JP4119952B2 (ja)	2008-07-16
CZ419597A3 (cs)	1998-03-18
WO1997001357A1 (en)	1997-01-16
DE69633180D1 (de)	2004-09-23
HK1010139A1 (en)	1999-06-17
NO321427B1 (no)	2006-05-08
SI0835137T1 (sl)	2006-04-30
PT835137E (pt)	2004-12-31
CZ286979B6 (en)	2000-08-16
JP2008101011A (ja)	2008-05-01
IL122119A0 (en)	1998-04-05
US6776985B1 (en)	2004-08-17
PL324289A1 (en)	1998-05-11
NO975813L (no)	1998-02-23
ES2253754T3 (es)	2006-06-01
AU708273B2 (en)	1999-07-29
KR100484883B1 (ko)	2005-09-02
ATE309000T1 (de)	2005-11-15
DK0835137T3 (da)	2006-03-06
KR19990028491A (ko)	1999-04-15
AU6415496A (en)	1997-01-30
EP0835137B1 (en)	2005-11-09
JPH11508768A (ja)	1999-08-03
CA2222559A1 (en)	1997-01-16
CN1189104A (zh)	1998-07-29
JP4848348B2 (ja)	2011-12-28
CN1187095C (zh)	2005-02-02
NO975813D0 (no)	1997-12-10
RU2187301C2 (ru)	2002-08-20

Publication	Publication Date	Title
JP4848348B2 (ja)	2011-12-28	ウイルス粒子産生カプセル化細胞
CA2450650C (en)	2007-08-28	Encapsulated cell therapy
Oran et al.	2019	Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells
Basic et al.	1996	Microencapsulation and transplantation of genetically engineered cells: a new approach to somatic gene therapy
Lahooti et al.	2000	Agarose enhances the viability of intraperitoneally implanted microencapsulated L929 fibroblasts
Catena et al.	2010	Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system
US20070172465A1 (en)	2007-07-26	Use of umbilical cord blood stem cells to treat ischemic event
AU724537C (en)	2001-07-19	Method for gene transfer to the central nervous system
JPH09503662A (ja)	1997-04-15	インシュリン分泌細胞系、その製造方法と使用
US20090196854A1 (en)	2009-08-06	Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
CN100418582C (zh)	2008-09-17	一种促进骨再生的微胶囊及其应用
JP3609395B2 (ja)	2005-01-12	哺乳類の不死化肝臓細胞
AU7248100A (en)	2001-03-22	Method for gene transfer to the central nervous system
Armeanu et al.	2001	In vivo perivascular implantation of encapsulated packaging cells for prolonged retroviral gene transfer
KR20120123225A (ko)	2012-11-08	피막된 이식세포 분리방법
HK1021801B (en)	2007-05-11	Composition for gene transfer to the central nervous system
Saller et al.	2000	Macrocapsules as a novel alternative for systemic in vivo delivery of virus vector